Active surveillance is the preferred option for men with low risk prostate cancer but the US lags behind other nations in its adoption. We examined the influence of urologist practice organization and intensity-modulated radiation therapy (IMRT) ownership on the use and rate of adoption of observation for men with incident prostate cancer.
INTRODUCTION AND OBJECTIVES:
Active surveillance is the preferred option for men with low risk prostate cancer but the US lags behind other nations in its adoption. We examined the influence of urologist practice organization and intensity-modulated radiation therapy (IMRT) ownership on the use and rate of adoption of observation for men with incident prostate cancer.
METHODS: Using national Medicare claims, we identified men with newly diagnosed prostate cancer from 2010 through 2014 and followed through 2015. We identified men not treated within 1 year of diagnosis as having undergone observation. We assigned each patient's urologist to a group practice and identified that group's organization (e.g. multispecialty group, single specialty group, solo practice) using data from the Medicare Data on Provider Practice and Specialty file. We also determined each practice's IMRT ownership using a claims algorithm. We fit mixed effects logistic regression models to identify predictors of observation and the rate of observation use over time, adjusting for patient factors.
RESULTS CONCLUSIONS: While observation is increasingly used for men with incident prostate cancer, the rate of increase varies by urologist group practice type, but independently of IMRT ownership. As physician groups consolidate, the resulting group practice landscape is important for understanding the continued adoption of active surveillance for prostate cancer.
Source of Funding: This work was supported by NCI F32CA232332 (PKM) and AHRQ R01HS257007 (BKH, VBS)

PD63-02 IMPACT OF THE AFFORDABLE CARE ACT ON PAYER DISTRIBUTION FOR UROLOGIC STONE SURGERY IN THE STATE OF CALIFORNIA
Scott Wiener*, David Bayne, San Francisco, CA; David Tzou, Tuscon, AZ; Thomas Chi, Marshall Stoller, San Francisco, CA INTRODUCTION AND OBJECTIVES: In March 2010 the Affordable Care Act (ACA) was signed into law, yet health insurance markets did not become fully operational until January 2014. We hypothesized that enactment of this legislation would alter the payer distribution for kidney stone patients undergoing ureteroscopy (URS), shockwave lithotripsy (SWL), and percutaneous nephrolithotomy (PCNL) in California (CA).
METHODS: We utilized CA's Office of Statewide Health Planning and Development (OSHPD) public inpatient and ambulatory surgical databases from 2011-2016 to examine URS, SWL, and PCNL operations for nephrolithiasis. Data was obtained on an aggregate level and split into two eras: 2011-2013 (pre-implementation) and 2014-2016 (post-implementation) . The proportion of patients/procedures was compared for payer type by Chi square test for independence before and after the ACA. ArcMap 10.5 Software (ERSI, Redlands, CA) was used to create the choropleth map of CA labor market regions.
RESULTS: A total of 86,437 procedures were performed from 2011-2013, while 95,866 were performed from 2014-2016. After 2014, the number of operations performed on Medicaid patients increased by 88% (from 8,878 to 16,717, p < .01, Figure) , while operations on the uninsured dropped by 67% (from 2,887 to 1,676, p < .01, Figure) with a ratio of 6.5:1 in favor of increased Medicaid operations. When examined by CA region, wide variability was noted with a range of -4% to þ214% for the change in procedures on Medicaid patients (Figure) . Counts for privately insured and Medicare patients increased without abrupt change after 2014.
CONCLUSIONS: The ACA drastically altered the payer mix for patients undergoing surgery for urinary stone disease, however not all geographic regions experienced the same degree of change. The ACA also may have improved access to stone surgery given INTRODUCTION AND OBJECTIVES: WISQOL, the first validated, disease-specific measure of HRQoL in kidney stone patients is a psychometric health status instrument i.e. it records frequency and intensity of symptoms and behaviors related to urinary stone disease (USD). Alternatively, health utilities assess HRQoL on a 0-1 scale (0[ death and 1[perfect health), and are the preferred metric for use in healthcare economic valuation. We sought to establish the statistical relationship between WISQOL scores and SF-6D and EQ-5D derived utility scores in USD patients. Construct validity of the utility measures was also assessed. METHODS: Consecutive adult USD patients, as well as young healthy controls without a history of USD were recruited. Each subject completed a health history survey, the SF-36 v2 and the EQ-5D questionnaires. USD patients additionally completed the WISQOL. SF-6D score was computed from 11 of the 36 items on the SF-36 v2 using validated, previously reported methodology.
Relationship between WISQOL and SF-6D / EQ-5D utility scores was examined using Pearson's correlation as well as multivariable regression with adjustment for baseline clinico-demographic characteristics. Utilities for USD patients vs. controls were compared using t-tests.
RESULTS: 91 patients and 78 controls were enrolled. SF-6D and EQ-5D utilities were significantly lower in patients compared with controls (Table 1) . For USD patients, SF-6D and EQ-5D utilities significantly correlated with WISQOL raw and subscale scores (Table 2) . On multivariable regression, 75.8% and 32.2% of the variance in SF-6D and EQ-5D utility scores respectively, was predicted by WISQOL raw score (p<0.0001 in each case).
CONCLUSIONS: WISQOL scores significantly correlated with, and had good predictive validity for the preference-based HRQoL scores in USD patients. SF-6D and EQ-5D utilities had excellent construct validity for USD. Our findings support these utilities as optimal preference-based HRQoL tools in USD. Results highlighted the need for comparative effectiveness research studies among patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). Based on these results, we constructed a research design for a trial entitled Comparison of Intravesical therapy and Surgery as Treatment Options (CISTO). We sought input from individuals with bladder cancer and their caregivers with a survey distributed to the BCAN PSN to query attitudes about randomization, study design, and relevant patient-centered outcomes.
METHODS: We conducted a web-based survey of the 1,300-member BCAN PSN. Responses were collected between March 6, 2017, and April 6, 2017. The survey included questions about bladder cancer diagnosis and treatment history, willingness to participate in clinical trials with different study designs, and the relative importance of various outcomes.
RESULTS: A total of 291 individuals previously diagnosed with bladder cancer responded, 201 of whom reported having had NMIBC, and 104 of whom had experienced recurrent NMIBC after BCG treatment. Among all respondents and within the subgroup of patients who experienced recurrent NMIBC after BCG, only 11% reported being willing to consent to randomization for a study of radical cystectomy versus intravesical therapy. The majority (76%) indicated a strong preference to keep their bladders. Therefore, a prospective observational cohort study was selected as the highest quality, most feasible and inclusive study design. Respondents recommended that the most relevant domains with which to compare our two treatments were survival and QOL, ranked in order of: 1) overall survival, 2) risk of spread of the cancer to other parts of the body, 3) overall QOL, 4) impact of the treatments on their caregiver or loved one, 5) urinary QOL, and 6) the costs or financial distress these treatments can incur. These outcomes were included as primary and secondary endpoints in CISTO.
CONCLUSIONS: Patient input from the BCAN PSN informed the design of a patient-centered pragmatic trial for bladder cancer, which was
